|[May 02, 2014]
RedPath Announces Presentations at 2014 Digestive Disease Week Meeting
PITTSBURGH --(Business Wire)--
RedPath Integrated Pathology, Inc., a leader in molecular diagnostics,
announced today that data from The National Pancreatic Cyst Registry, a
multi-institutional prospective study of 492 patients with pancreatic
cysts, has been accepted for oral presentation at the Digestive Disease
Week (DDW) Annual Meeting taking place May 3-6, 2014, at McCormick Place
Results from the study show that, when cytology results are
non-malignant, integrated molecular pathology (IMP) can accurately
differentiate cysts with low versus high malignant potential by
incorporating DNA molecular analyses with first-line tests (cytologic
atypia, CEA, imaging).
Dr. Thomas Kowalski, Director of Gastroenterology and Associate
Professor of Medicine at Thomas Jefferson University will present the
data on Tuesday, May 6 at 2:20pm (CT).
In addition, research data on the use of IMP in patient management of
pancreatic cysts will be presented in a poster on Monday, May 5, 2014,
and data on the use of IMP in Barrett's Esophagus will be presented in a
poster on Tuesday, May 6, 2014.
Details of the presentations are as follows:
Title: Management strategy of pancreatic cys patients based on
integrated molecular pathology in 492 patients: The final results of a
Poster session: ASGE - EUS 2
Mohammad Al-Haddad, MD, et al
Session date: Monday, May 5,
Location: South Hall
Title: Clinical utility of using second-line integrated molecular
pathology testing in addition to first-line test algorithms to determine
the malignant potential of pancreatic cysts.
title: Pancreatic cancer: Now and in the future
Kowalski, MD, Director of Gastroenterology, Associate Professor of
Medicine, Thomas Jefferson University
Session date: Tuesday, May 6,
Presentation time: 2:20pm (CT)
Title: Mutational load as a predictor of progression in Barrett's
Esophagus: a longitudinal study.
session: ASGE - Esophagus
Authors: Ebubekir Daglilar, MD, et al
date: Tuesday, May 6, 2014
Location: South Hall
About RedPath Integrated Pathology
RedPath Integrated Pathology, Inc. is a Pittsburgh-based molecular
diagnostics laboratory focused on providing novel solutions for
clinicians. RedPath's patented PathFinderTG® platform
produces mutational profiles to help physicians resolve complex
diagnostic dilemmas in patients who are at risk of cancer. RedPath
performs all clinical testing and R&D in its state-of-the-art,
CLIA-certified and CAP-accredited laboratory.
The PathFinderTG platform is supported by more than 20 years of
scientific and clinical research, and studies using it have been
published in more than 200 peer-reviewed journals, including The New
England Journal of Medicine. Based on the strong clinical data
supporting this platform, RedPath has received positive coverage
decisions from Medicare and private payers. For more information about
RedPath Integrated Pathology visit www.redpathip.com
or contact Andrew Mignatti at 412-224-6100.
[ Back To Technology News's Homepage ]